Merck & Co., Inc. 8-K

What Happened

• Merck & Co., Inc. filed an 8-K disclosing results of its Annual Meeting of Shareholders held May 26, 2026. All 13 nominated directors were elected to the Board. The non-binding "say-on-pay" advisory vote and the ratification of the company’s independent auditors were approved by shareholders, while three shareholder proposals were defeated.
• There were 283,983,197 broker non-votes recorded on several matters. Notable vote tallies included: Douglas M. Baker, Jr. (1,849,536,622 FOR); Patricia F. Russo received the largest opposition among nominees (1,636,745,520 FOR, 217,186,188 AGAINST). Say-on-pay: 1,730,192,132 FOR, 109,310,633 AGAINST. Auditor ratification: 2,011,579,504 FOR, 126,487,980 AGAINST.

Key Details

• Date of meeting: May 26, 2026. Filing: Form 8-K (filed May 28, 2026).
• Directors elected: all 13 nominees (including Douglas M. Baker, Jr., Mary Ellen Coe, Risa J. Lavizzo‑Mourey, Stephen L. Mayo, Paul B. Rothman, Patricia F. Russo).
• Say-on-pay (advisory): 1,730,192,132 FOR; 109,310,633 AGAINST; 18,017,635 abstentions; 283,983,197 broker non-votes.
• Shareholder proposals on (1) DEI risks in federal contracting, (2) healthcare coverage gaps, and (3) political contributions were defeated: DEI (22,754,046 FOR vs. 1,812,455,404 AGAINST), Healthcare gaps (23,597,628 FOR vs. 1,811,874,302 AGAINST), Political contributions (227,074,175 FOR vs. 1,606,594,343 AGAINST).

Why It Matters

• Election of the full slate of directors and approval of auditor ratification maintain board continuity and governance oversight. The approval of the non‑binding say-on-pay means shareholders gave broad support to Merck’s executive compensation program for now.
• The clear defeats of the shareholder proposals signal limited shareholder appetite at this meeting for the requested additional reporting on DEI, healthcare coverage gaps, and political contributions; the political contributions proposal drew notably more support than the other two but still failed. Investors should note the vote margins and any potential follow‑up disclosure or engagement Merck may provide in response.